PEC (6446) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 藥華藥

PEC (6446) reported revenue of NT$2.84 billion for Oct 2026, +102.0% year on year and +7.6% from the previous month. Revenue for Jan–Oct 2026 was NT$22.57 billion (+85.7% year on year).

Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$2.64 billion). →

Year-on-year revenue growth: 25+ months in a row. →

In Oct 2026, it ranked No. 1 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$914.3 million24/10Nov 2024 NT$1.02 billionDec 2024 NT$1.13 billionJan 2025 NT$1.06 billionFeb 2025 NT$1.02 billion25/02Mar 2025 NT$1.18 billionApr 2025 NT$1.23 billionMay 2025 NT$1.18 billionJun 2025 NT$1.2 billion25/06Jul 2025 NT$1.3 billionAug 2025 NT$1.27 billionSep 2025 NT$1.32 billionOct 2025 NT$1.4 billion25/10Nov 2025 NT$1.55 billionDec 2025 NT$1.92 billionJan 2026 NT$1.58 billionFeb 2026 NT$1.6 billion26/02Mar 2026 NT$1.94 billionApr 2026 NT$2.06 billionMay 2026 NT$2.46 billionJun 2026 NT$2.33 billion26/06Jul 2026 NT$2.51 billionAug 2026 NT$2.62 billionSep 2026 NT$2.64 billionOct 2026 NT$2.84 billion26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$2.84 billion+102.0%+7.6%
Sep 2026NT$2.64 billion+100.0%+0.7%
Aug 2026NT$2.62 billion+105.4%+4.4%
Jul 2026NT$2.51 billion+92.6%+7.5%
Jun 2026NT$2.33 billion+94.9%-5.1%
May 2026NT$2.46 billion+108.5%+19.1%
Apr 2026NT$2.06 billion+68.3%+6.4%
Mar 2026NT$1.94 billion+64.4%+21.2%
Feb 2026NT$1.6 billion+56.7%+1.2%
Jan 2026NT$1.58 billion+49.8%-17.8%
Dec 2025NT$1.92 billion+69.9%+23.8%
Nov 2025NT$1.55 billion+53.0%+10.6%
Oct 2025NT$1.4 billion+53.6%+6.5%
Sep 2025NT$1.32 billion+41.3%+3.4%
Aug 2025NT$1.27 billion+41.3%-2.1%
Jul 2025NT$1.3 billion+48.0%+8.8%
Jun 2025NT$1.2 billion+41.1%+1.5%
May 2025NT$1.18 billion+49.2%-3.8%
Apr 2025NT$1.23 billion+83.7%+3.9%
Mar 2025NT$1.18 billion+111.5%+15.5%
Feb 2025NT$1.02 billion+73.8%-3.2%
Jan 2025NT$1.06 billion+107.9%-6.8%
Dec 2024NT$1.13 billion+67.8%+11.5%
Nov 2024NT$1.02 billion+138.9%+11.0%
Oct 2024NT$914.3 million+67.0%-1.9%

Jan–Oct 2026 cumulative: NT$22.57 billion (+85.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: PEC vs Lotus Pharm / PEC vs Bora / PEC vs Great Tree Pharmacy

CompanyRevenueYoY
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%
GKB1707NT$748.3 million-30.8%

Company remark (original Chinese)

本月及本年累計營收較去年成長,主要來自認列美國子公司PharmaEssentia USA Corp.之營收。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16